Greenwich LifeSciences Inc Sustainability Reports
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy designed to prevent breast cancer recurrences in patients who have previously undergone surgery.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
FIGI: BBG00V6PT8D6
2 reports from 2021 to 2024
Company Profile
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy designed to prevent breast cancer recurrences in patients who have previously undergone surgery.
Reports
2 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
